William Blair Has Bearish Forecast for BMY FY2026 Earnings
Equities research analysts at William Blair decreased their FY2026 earnings per share estimates for shares of Bristol-Myers ...
William Blair Has Bullish Forecast for MOD FY2025 Earnings
Equities research analysts at William Blair upped their FY2025 EPS estimates for shares of Modine Manufacturing in a note ...
Hosted on MSN1d
William Blair Initiates Coverage of Rubrik (RBRK) with Market Perform Recommendation
Fintel reports that on February 7, 2025, William Blair initiated coverage of Rubrik (NYSE:RBRK) with a Market Perform ...
Rubrik initiated with a Market Perform at William Blair
William Blair initiated coverage of Rubrik (RBRK) with a Market Perform rating.Maximize Your Portfolio with Data Driven Insights:Leverage the ...
Mersana Therapeutics initiated with an Outperform at William Blair
William Blair initiated coverage of Mersana Therapeutics (MRSN) with an Outperform rating.Maximize Your Portfolio with Data Driven ...
Why Is Neurocrine Biosciences Stock Trading Lower On Friday?
Neurocrine Biosciences Q4 earnings topped forecasts, but revenue slightly missed. Analysts see Ingrezza's long-term growth ...
BioSpace1d
FDA Approval of Vertex’s Non-Opioid Journavx Signals New Era in Pain Treatment
If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...
medtechdive1d
BD plans split from life science business to fuel medtech investment
CEO Tom Polen said BD will “double down on shifting our portfolio, both organically and inorganically through tuck-in M&A, ...
Investing4d
Palantir stock surges despite Underperform rating from William Blair
Despite this, William Blair maintained an Underperform rating on the stock. Palantir's financial outlook for 2025 anticipates revenues of $3.75 billion, which is above the consensus estimate of $3 ...